Targeted Approaches to CMV Management: Alleviating the Patient Burden from Prevention to Refractory Disease

Program Overview

Cytomegalovirus (CMV) can be a life-altering reality for patients after solid organ transplant (SOT). Limited antivirals and rising resistance make treatment a challenge. Join Drs. Deepali Kumar and Raymund R. Razonable as they share practical, evidence-based strategies to tackle the most common serious infectious complication after SOT. The faculty will be joined by a patient who will speak directly about how her transplant journey was complicated by CMV and what it means for her to navigate this challenging infection on her path towards healing.

 

1.0 CE Credit(s)

Target Audience

Infectious disease, transplantation, and internal medicine clinicians

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Employ updated guidelines in the antiviral prophylaxis and initial management of cytomegalovirus (CMV) in solid organ transplant (SOT) patients
  • Create treatment strategies for refractory or resistant CMV in SOT recipients that integrate the latest guidelines
  • Manage adverse events related to CMV antivirals

Activity Faculty

62-26-1892-SM-002 ATC Kumar

Deepali Kumar, MD, MSc, FRCPC, FAST

Professor, Department of Medicine
University of Toronto
Program Medical Director, Ajmera Transplant Program
University Health Network
Director, University of Toronto Transplant Institute
Toronto, ON, Canada

Razonable_Raymund_2021

Raymund R. Razonable, MD, FIDSA, FAST 

Professor, Medicine
Associate Chair of Education, Division of Infectious Diseases
Mayo Clinic
Rochester, MN

Supporter Statement

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Provider Statement

Provided by RMEI Medical Education, LLC.

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI will disclose to learners the presence or absence of relevant financial relationships for all persons in control of content before the learner engages in the education.

Faculty

RMEI will disclose to learners the presence or absence of relevant financial relationships for all persons in control of content before the learner engages in the education.

 

Planners and Managers

RMEI will disclose to learners the presence or absence of relevant financial relationships for all persons in control of content before the learner engages in the education.

Joint Accreditation Statement 

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Credit Designation

Physician Continuing Medical Education 
RMEI Medical Education, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education 
RMEI Medical Education, LLC designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-26-001-L01-P)
Type of Activity: Knowledge

Method of Participation and Request for Credit

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be e-mailed to you within 3 weeks. If you have questions regarding the receipt of your e-mailed certificate, please contact RMEI via e-mail at [email protected].

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2026. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | www.RMEI.com | (866) 770-RMEI

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources